To assess the cost-effectiveness of orlistat plus a calorie-controlled diet compared with a calorie-controlled diet alone for the treatment of overweight and obese patients in Ireland. DESIGN: Economic modelling techniques using published international efficacy data and Irish cost data were used to estimate the cost-effectiveness of orlistat in obese patients when only responders to treatment (ie achieve 5% weight loss after 3 months of treatment) continue orlistat after 3 months. The model incorporated known relationships between weight loss and quality of life (utility) gain, and weight loss and reduction in risk of type 2 diabetes (T2DM) to predict the impact of weight loss on qualityadjusted-life-years (QALYs) gained and on the onset of T2DM. The costs associated with each treatment arm included the acquisition cost of orlistat, cost of a calorie-controlled dietary programme and monitoring and treatment costs associated with T2DM. An Irish health-care perspective was taken for the analysis, based on 2003 costs. SUBJECTS: Weight loss data on 1386 patients from five pivotal orlistat clinical trials with at least 12 months duration were pooled (two American and three primarily European studies). All the studies were randomized, placebo-controlled, multicentre trials with a similar design. The inclusion criteria were BMI Z28 kg/m 2 , age Z18 y, no diagnosed T2DM and the ability to lose 2.5 kg in weight during the introductory period. MEASUREMENTS: Cost effectiveness was modelled from these data and presented as incremental cost per QALY. RESULTS: When orlistat treatment plus a calorie-controlled diet was compared with a calorie-controlled diet alone, the incremental cost per year was h478. The number needed to treat (NNT) to gain one QALY was estimated to be 35. The incremental cost per QALY gained was within the range considered cost-effective at h16 954. Sensitivity analysis demonstrated an incremental cost per QALY of h11 000-35 000 under a variety of assumptions. CONCLUSIONS: Our model suggests that orlistat is effective and cost-effective in obese patients, if after 3 months of treatment, only treatment responders continue treatment.
Introduction
Obesity is classified by the World Health Organization (WHO) as a disease (ICD code ¼ E66) and defined in terms of body mass index (BMI) in kg/m 2 , which is based on a combination of height and body weight. People with a BMI of 25-29.9 kg/m 2 are defined as overweight and people with a BMI of 30 kg/m 2 or more are defined as obese. The Irish diet generally tends to be higher in fat than the average European diet given the agricultural background, but in other respects is similar to other European countries. During the last 10 y, the number of obese people has increased substantially in Ireland with latest estimates suggesting a prevalence of between 13 and 18%. 1, 2 It has been shown that obese people run a greater risk than people of normal weight of developing secondary diseases (eg type 2 diabetes (T2DM), 3, 4 high blood pressure and cardiovascular disease 5 ) and thus also an increased risk of early death. 6 Obese patients are almost 28 times more likely to develop T2DM, compared with nonobese individuals. 7 Obesity also has a negative effect on quality of life both physically and psychologically. 8 International estimates of the disease costs for obesity and related secondary diseases range from 2 to 6% of national total health-care expenditure. [9] [10] [11] [12] [13] [14] [15] [16] Based on these international estimates and Ireland's total annual healthcare cost of 10 billion euros, 17 obesity costs may account for at least 200 million euros annually in this country. Added to this are costs for sick leave and early retirement, which are at least as high. 18 Much can be gained economically by reducing body weight in obese patients. For example, the addition of orlistat to lifestyle changes has been shown to increase weight loss and reduce the incidence of T2DM by 37% more than dietary intervention alone in obese individuals. 19 The importance of economic evaluation to the appropriate allocation of health-care resources in Ireland has been discussed previously. 20, 21 The aim of this study was to evaluate the cost-effectiveness of adding orlistat to a calorie-controlled diet in obese individuals.
Methods
Overview Health-care costs and benefits (ie quality-adjusted-life-years (QALYs) gained) were estimated by comparing orlistat in combination with a 12-month dietary programme with a dietary programme alone in the treatment of obese patients without diabetes. In line with National Institute of Clinical Excellence (NICE) guidance on orlistat 22 and summary of product characteristics (SPC), we assumed that after 3 months of treatment with orlistat, only treatment responders (ie those who achieve at least 5% reduction in body weight) continue treatment with orlistat. Our model used data on weight loss at 12 months with orlistat in combination with a dietary programme from five randomized, placebo-controlled trials. The model also incorporated known relationships between weight loss and quality of life (utility) gain, and weight loss and reduction in risk of T2DM
to predict the impact of weight loss on QALYs gained and on reduced time with T2DM. The costs associated with each treatment arm included the acquisition cost of orlistat, cost of a calorie-controlled dietary programme and monitoring and treatment costs associated with T2DM. The difference in total costs between the treatment arms were compared with the difference in QALYs gained to estimate the incremental cost per QALY for orlistat. All costs were evaluated from the perspective of the Irish health-care system. The model was run for an 11-y period (treatment year plus 10 y post treatment) to capture treatment effects on diabetes incidence and associated costs. The treatment algorithm is summarized in Figure 1 . Key demographic and weight loss data used in the model are summarized in Table 1 .
Weight loss data
Subjects and weight loss inputs to model. Data on 1386 patients from five pivotal clinical trials with at least 12-month duration were pooled (two American and three primarily European studies). [23] [24] [25] [26] [27] All the studies were randomized, placebo-controlled, multicentre trials with a similar design. The inclusion criteria were BMI Z28kg/m 2 , age Z18 y, no diagnosed T2DM and the ability to lose 2.5 kg in weight during the introductory period. During the 4-week single-blind introductory period, patients received a caloriereduced diet. Patients who achieved the initial weight loss of at least 2.5 kg were randomized to a one-year double-blind treatment with orlistat plus calorie-reduced diet or placebo plus calorie-reduced diet. A flow diagram indicating the numbers of patients at different time points based on the meta-analysis is presented in Figure 2 . 
Cost-effectiveness of orlistat
LA Lacey et al Predicting QALYs gained due to weight loss (ie changes). Obesity affects patients' health-related quality of life (QoL) and has been shown to be associated with deteriorations in functional status and well-being. [28] [29] [30] [31] [32] Utility scores offer an alternative method of QoL assessment. Utility refers to the worth of a health state and is measured by evaluating preferences by an individual or society for the given state. Utility scores go from 0 (death) to 1.0 (perfect health). Changes in states can be expressed in incremental utility terms and converted to QALYS. These units weight an individual's duration in a health state by the average utility of that health state. Thus if a patient with a severe illness lived for 10 y with a utility score of 0.3, this would be equivalent to 10 Â 0.3 or 3 QALYs. The effect of changes in BMI on patient utility was examined by Hakim et al 33 using patient reported QoL and BMI data from a clinical study. 34 Using a conversion algorithm developed by Torrance, 35 the authors converted the QoL scores into utility weights and established that a one unit decrease in BMI over a 1-y period was associated with a 0.017 gain in utility (utils). 33 The time horizon for evaluating QALY gains was based on a 3-y post-treatment perspective (see Other key assumptions). The weighted average gain in QALYs for the average orlistat patient is calculated using estimates of QALYs gained for orlistat responders and orlistat nonresponders and known percentages of responders and nonresponders with orlistat. The incremental QALYs gained for orlistat plus a calorie-controlled diet compared with a calorie-controlled diet (placebo) is calculated by subtracting QALYs gained with placebo from QALYs gained with average orlistat patient.
Predicting the change in incidence of T2DM with change in BMI. The correlation between BMI and the annual incidence of T2DM was calculated based on two large American prospective epidemiological studies, the Nurses Health Study and the Health Professionals Follow-up Study. 36 For men with BMI ¼ 35 kg/m 2 , the annual incidence of diabetes was estimated as 1.4% and for men with BMI ¼ 25 kg/m 2 as 0.04%. For women, the equivalent figures were 0.61% and 0.13%. Based on these data, it was estimated that a 10% reduction in BMI should reduce the annual incidence of In the model, orlistat nonresponders were allocated the weight loss and utility gain associated with placebo nonresponders because the model assumed orlistat responders stop treatment after 3 months. In the clinical trials, orlistat treatment continued irrespective of response at 3 months.
Cost-effectiveness of orlistat LA Lacey et al diabetes by approximately 30%. As the change in the annual incidence of T2DM in our model is directly linked to a change in weight loss, the difference in annual incidence of T2DM between the two arms will disappear when patients regain their initial weight. The temporary reduction in the annual incidence will effect the cumulative incidence of T2DM because it reduces/delays the number of patients who develop diabetes. We assumed that the differences in cumulative incidence of T2DM would last for 10 y. Therefore a time horizon of 11 y was used for effects on diabetes costs in the model.
Sustained weight loss. As weight loss affects both the utility gained and incidence of T2DM, it is important to be clear about the sustainability of weight loss following the 12-month treatment period. For the base-case analysis, we assumed that patients achieved their maximum weight loss at 12 months and regained their original weight at a uniform rate over the following 3 y (ie in line with NICE recommendation).
22
Cost data A summary of item costs used is presented in Table 2 .
Costs of orlistat
The cost for orlistat is h65.80 per pack of 84 orlistat capsules (pharmacy costs). 37 The cost per capsule is h0.78. We assumed that three capsules per day were used. The cost for orlistat includes 3 months of treatment for all in the first 3 months and 9 additional months treatment for those who respond at 3 months.
Cost of dietary programme per month
In the base-case calculation, we assume that all patients in the study who did not discontinue all treatment continue with a calorie-reduced diet for the whole 12-month period.
We have assumed that a patient participating in the programme for 12 months will visit the GP twice (at the start of the programme and in month 3) and the dietitian Figure 2 Summary of meta-analysis of five pivotal orlistat trials. Cost-effectiveness of orlistat LA Lacey et al four times (baseline, months 3, 6 and 12). As these costs are common to both arms they have no bearing on the costeffectiveness evaluation.
Diabetes monitoring and treatment health-care costs
The annual cost for monitoring and treating patients with T2DM was estimated to be h2945 on the basis of a recently completed burden of diabetes study in Ireland. 38 Incremental cost per QALY analysis. The incremental cost of orlistat plus a calorie-controlled diet vs calorie-controlled diet alone (placebo) is estimated in the following steps:
(i) The acquisition cost of orlistat is calculated for orlistat responders and non responders and for calorie-controlled diet alone (placebo). (ii) The diabetes-related savings are calculated for orlistat responders and nonresponders alone. (iii) The weighted average cost of an average orlistat patients is calculated using known percentages of responders and nonresponders and cost data from steps (i)-(ii), in addition to adding the cost of the dietary programme. (iv) The cost of an average patient on a calorie-controlled diet (placebo) is calculated using data on diabetes savings and cost of dietary programme. (v) The incremental cost is obtained from the difference in average costs between orlistat plus calorie-controlled patients and calorie-controlled diet alone (placebo) patients.
In the final step, the incremental cost per QALY is calculated as follows: Incremental cost of orlistat plus calorie-controlled diet less calorie-controlled diet only (placebo)/incremental QALYs associated with orlistat plus calorie-controlled diet less QALYs associated with caloriecontrolled diet alone (placebo).
Discounting. In the base-case analysis, we used a discounting rate of 3% for costs and health effects.
Other key assumptions. After the end of treatment, we assume that it will take 3 y for treatment responders to return to their original weight, that is, the weight they had before the beginning of treatment. In the model, orlistat nonresponders are allocated the weight loss associated with placebo nonresponders because the model assumed orlistat nonresponders stopped treatment after 3 months. This differed from the clinical trial where treatment continued, irrespective of response. We assumed three capsules of orlistat were taken daily which is generous since, on average, patients take 2-2.5 per day. We calculated only the cost savings associated with the reduction in T2DM and, not the reduction in dyslipidaemia and/or hypertension.
Sensitivity analysis. To test the robustness of our analysis we carried out a sensitivity analysis looking at the effects of: 
Results
Base-case After 12 months, patients receiving orlistat had lost 11.6% in weight compared with 7.9% in those receiving placebo. Orlistat responders lost 15.5% of their initial weight. In addition, the criterion of a response (ie Z5% loss in weight) at 3 months was met by twice as many patients in the group treated with orlistat plus a calorie-reduced diet (49%) as in the group who only received a calorie-reduced diet (26%). No correction was made for those who dropped out during the 3-12-month period as the % dropouts for orlistat and placebo were similar.
As a result of weight loss in the 52-week period, the model predicted that orlistat responder patients had a 0.14-y shorter period of time with diabetes over the 11-y modelling period, than those who had not lost weight (Table 3) . Placebo-treated patients had a 0.07-y shorter period of time with diabetes. For orlistat-responders this was associated with a saving of h353 in diabetes-related costs over the same period. This should be compared with savings of h119 and h179 for orlistat nonresponders and placebo (diet alone) ( Table 3 ). The incremental cost for the average orlistattreated patient was h478. The net utility gain in the orlistat arm was 0.028 compared with placebo but the orlistat responders gained 0.090 compared to placebo patients as a result of 1 year's orlistat treatment (Table 3 ). The number needed to treat (NNT) to achieve a gain of one QALY was 35. The incremental cost per QALY gained was h16 954.
Sensitivity analysis
Sensitivity analysis demonstrated an incremental cost per QALY of h11 000-35 000 under a variety of assumptions (Table 4) . Using 1-y data from the XENDOS study in the model, we estimated a cost per QALY of h14 950. This was lower than the base-case because of a higher QALY gain for orlistat. The most critical assumptions were duration of sustained effect and daily dose. For example, the lowest cost per QALY arose when it was assumed that patients took only 2.1 tablets per day. This resulted in lower drug costs. The highest cost per QALY arose when it was assumed that all weight was regained within the first year post treatment as the QALYs gained were lower with orlistat.
Discussion
This analysis demonstrates the cost-effectiveness of orlistat in the general obese nondiabetes population, if after 3 months, only responders continue treatment with orlistat.
Cost-effectiveness of orlistat LA Lacey et al The 11.6% weight loss in the average orlistat patient and the 15.5% average weight loss in orlistat responders represents a combination of the effects of active treatment and dietary control. The importance of dietary control is demonstrated by the average 7.9% weight loss in patients on dietary control alone (ie placebo).
We believe we were conservative in the assumptions used in our analysis since, for example, we considered the mean dose of orlistat to be three tablets daily (in reality it is 2-2.5 per day). In addition, we calculated the cost savings related to a reduction in T2DM only, and did not include savings related to reductions in dyslipidaemia and/or hypertension.
Our base-case analysis assumed that it takes 3 y for weight to be regained in the orlistat group, on cessation of treatment. This is consistent with weight regain assumptions reported in the NICE Orlistat guidance. 22 However, when other scenarios were tested assuming shorter durations to regain weight, all predicted incremental cost effectiveness ratios (ICERs) were within the range considered costeffective.
One limitation of this study is that the efficacy/weight loss data taken from published trials may not be representative of the weight loss achieved in an Irish setting. While no randomized controlled trial has been carried out in Ireland Cost-effectiveness of orlistat LA Lacey et al comparing orlistat plus a calorie-controlled diet vs diet alone, the results of an audit of 5251 patients attending weight loss clinics in Ireland reported that orlistat plus a caloriecontrolled diet produced 62% greater weight loss than a calorie-controlled diet alone. 8 Another point in favour of the model's application to Ireland is that the calorie-controlled diet used in Irish weight loss clinics is broadly identical to that used in the orlistat trials (ie is less that 30% fat with modest calorie restriction).
Orlistat's cost-effectiveness has been examined in different patient groups and in different countries including the UK, 39 in Belgium 40 and the US 41 and not unexpectedly the ICERs vary, due in part to differences in health-care costs across the countries and patient characteristics. Cost-effectiveness ratios range from h3462-19 986/life year gained in Belgium to h15 084(d10 433)-h66 334 (d45 881)/QALY in the UK health technology assessment. 42 The cost-effectiveness ratio estimated in this study can be compared with that of other interventions, for example Taxanes for breast cancer (h22 410 (d15 500)), zanamivir for at-risk populations (h29 500 (d20 400)), asthma inhalers (h7229 (d5000)). These and others have been described in a recent review. 43 There is no stated ICER threshold in Ireland but an ICER of about h29 500-43 500 (ie d20 000-30 000) per QALY gained is likely to be considered cost-effective by NICE in the UK. 44 All the scenarios tested in our analysis proved cost-effective by these criteria. It has been suggested that resources within the Irish health-care system are far from adequate to prevent the occurrence of obesity or to treat already obese individuals. 45, 46 The causes of obesity are multifactorial and so a multipronged approach is necessary if obesity is to be managed effectively. Our analysis suggests that orlistat represents one efficacious and cost-effective approach.
Conclusions
Our model suggests that orlistat is effective and cost-effective in obese patients, if after 3 months of treatment, only treatment responders continue treatment.
